Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Articles

The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.

FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy

Iron deficiency represents more than a medical condition; it is a reflection of persistent health disparities, according to an editorial published in The Lancet Haematology.

A Case for Iron Deficiency as a Marker of Inequality in Care Access and Treatment

Use of in-room air purifiers with HEPA-14 filters did not result in a significant reduction of acute respiratory infections.

In-Room Air Purifiers Could Impact RSV Incidence Among Older Adults

Cameron Santoro is an associate editor for 

), AJMC.com, and The Center for Biosimilars

Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster competition, and increase biosimilar access for patients.

Addressing Patent Hurdles, Payer Barriers, and Interchangeability

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

In-depth interviews with decision-makers, stakeholders, and researchers on timely and emerging trends in clinical data, health policy, value-based care, and more!

1rem

Emerging Agents for Myelofibrosis

Videos

Overview of Myelofibrosis

Diagnosis of Myelofibrosis

Prognosis and Risk Stratification of Myelofibrosis

Goals of Therapy and Starting Therapy for Myelofibrosis

NCCN Guidelines and Anemia Treatment

Mechanism of JAK Inhibitors and a Review of Ruxolitinib

Long-Term Survival and Adverse Effects With Ruxolitinib

Emerging Agents and Review of Fedratinib

Comparison of Ruxolitinib vs Fedratinib and Practical Implications

Pacritinib and the Practical Implications

Evolution of Myelofibrosis and Efficacy & Toxicity of Therapy

Symptoms and Patient Progression

Future of Therapy and Final Thoughts on Myelofibrosis